14 March 2025
Financings have come alive and we dig dig dig into them, between the huge LBO for Walgreens, the Hinge Health preliminary IPO filing, and ModMed’s majority stake sale. Anne Wojcicki keeps trying to buy her own company for dimes, but put a slightly sweeter offer on the table–if you like waiting. Elizabeth Holmes is waiting for the courts to see it her way. And our guest Perspectives from the field presents a view of improving telehealth policy on opioid use treatments.
News roundup: MSK is ‘it’ with Hinge Health’s IPO filing, Vori Health’s $53M raise, Dario Health’s 33% revenue increase; CoachCare buys VitalTech, ModMed investor sells majority stake, Health NZ uses Excel–only; Holmes gets rehearing extension (IPO, investment unfreezes despite market turmoil, and two ‘I can’t believe it’ stories from NZ and Ms. Holmes’ continuing appeals)
Sycamore Partners taking on 83% debt in financing their Walgreens leveraged buyout–some observations (Another season for leveraged buyouts, including a walk back to the LBO Golden Age of the 1980s. Can Walgreens do better than this?)
Update: Wojcicki increases 23andMe per share offer to $2.94 from $0.41–but there’s three contingency ‘catches’, and more (Another amazing penny-ante offer for 23andMe. Will the board succumb? Is there a choice?)
Perspectives: How the DEA Telehealth Extension Impacts Patient Access to Opioid Use Disorder Treatments & Buprenorphine Prescriptions (A clinician’s view from the field)
The $10 billion Walgreens take-private deal with Sycamore: what you need to know (We look into the deal’s devilish details, and what Walgreens might look like in a year or two)
Last week: Breaking news on ongoing stories dominated this week, with much of the industry off at HIMSS. As predicted last week, Walgreens Boots Alliance nears a take-private acquisition that would break up this legendary company. 23andMe went from a strong offer backed by an investor to their exit in a week, with the CEO’s latest lowball bid rejected in 24 hours. Masimo seems to have turned their business corner and made Mr. Market happy, but can’t shake off legal entanglements with their former CEO. And the last sad dregs of Theranos played out in the Ninth Circuit Court of Appeals, with Holmes’ and Balwani’s likely last appeals denied.
Masimo updates: optimism around healthcare despite ’24 losses, former CEO Kiani files notice in California on compensation owed (A turnaround for Masimo in 2025, but there’s a new California legal tangle with their former CEO)
Theranos’ denouement: Holmes and Balwani lose their appeals (Ninth Circuit saw District Court errors as ‘harmless’ to verdicts and sentencing, $452 million restitution stands–but Holmes gets a People cover)
Breaking: 23andMe sale bids slide from $2.53 per share to $0.41 to none in 11 days, as board rejects CEO’s offer (Unbelievably, investor exits in a week, Wojcicki’s solo low bid rejected by board in a day)
Breaking: Sycamore Partners’ $10B deal for Walgreens may close this week–reports (Updated for debt financing details) (A legendary public company to go private and break up into three parts.)
* * *
Advertise on Telehealth and Telecare Aware
Support not only a publication but also a well-informed international community.
Contact Editor Donna for more information.
Help Spread the News
Please tell your colleagues about this free news service and, if you have relevant information to share with the rest of the world, please let me know!
Donna Cusano, Editor In Chief
donna.cusano@telecareaware.com
Telehealth & Telecare Aware – covering news on latest developments in telecare, telehealth and eHealth, worldwide.
Most Recent Comments